Thailand's Food and Drug Administration on Tuesday completed the registration of a generic version of Abbott Laboratories' antiretroviral drug Aluvia for use under the country's compulsory licensing program, the Bangkok Post reports.
The generic version is manufactured by Indian pharmaceutical company Matrix Laboratories. The Thai Ministry of Public Health in June confirmed that it would continue with its plan to issue a compulsory license for the drug after Abbott and the health ministry could not reach a price agreement during negotiations.
Clinical Trials - Drug development and Approval
The Drug development process is a complex one, where the experimental drug or treatments goes through various stages before it could get rejected or approved.
Advertisement
The Thai government in January issued a compulsory license to produce a lower-cost version of Abbott's Kaletra. The drug company in May offered to sell Aluvia, an updated version of Kaletra, at a reduced price in Thailand on the condition that the country agreed not to allow generic versions of the drug into the market, Siriwat Thiptaradol, secretary-general of the Thai FDA, said.
Abbott offered to sell Aluvia for about 34,000 baht, or $1,000, per person annually. Matrix offered to sell a generic version of Aluvia to Thailand for 24,324 baht, or $695, per person annually.
![India to Set Up Centralised Drug Licensing Authority]( "India to Set Up Centralised Drug Licensing Authority")
The government is planning to disallow states from issuing licences to drug companies and to set up a federal authority instead on the lines of the US Food and Drugs Administration
Vichai Chokewiwat, chair of the Government Pharmaceutical Organization and the health ministry's Committee on Compulsory Licensing, said GPO soon will import the first shipment of the generic version of Aluvia from Matrix.
According to Siriwat, the registration process took more than three months to complete. The shipment from Matrix will include enough doses of the drug for 8,000 people during the next six months, the Post reports.
Source: Kaiser Family Foundation
LIN /J
India to Set Up Centralised Drug Licensing Authority
The government is planning to disallow states from issuing licences to drug companies and to set up a federal authority instead on the lines of the US Food and Drugs Administration
Advertisement
Vichai Chokewiwat, chair of the Government Pharmaceutical Organization and the health ministry's Committee on Compulsory Licensing, said GPO soon will import the first shipment of the generic version of Aluvia from Matrix.
According to Siriwat, the registration process took more than three months to complete. The shipment from Matrix will include enough doses of the drug for 8,000 people during the next six months, the Post reports.
Source: Kaiser Family Foundation
LIN /J
FDA Approves Merck’s ARV Drug Raltegravir
Merck on Friday announced that FDA has approved its antiretroviral drug raltegravir for use by HIV-positive people who have not responded to other treatments, the Wall Street Journal reports.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
Women using hormonal contraception, along with their healthcare providers, should explore alternative pain relief options instead of NSAIDs.
